DETECTION OF KI-67 PROLIFERATION RATE IN BREAST-CANCER - CORRELATION WITH CLINICAL AND PATHOLOGICAL FEATURES

被引:60
作者
VERONESE, SM
GAMBACORTA, M
机构
[1] Ist. di Anatomia Patologica, Ospedale di Niguarda, 20162 Milan
关键词
BREAST IMMUNOCHEMISTRY KI-67 MONOCLONAL ANTIBODY; PROLIFERATIVE ACTIVITY;
D O I
10.1093/ajcp/95.1.30
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In situ determination of proliferative activity was performed on 203 breast cancers by use of Ki-67 monoclonal antibody and immunohistochemical methods. Tumor proliferation rate was analyzed and correlated to tumor size and nodal status. The relationship between Ki-67 proliferative activity and nuclear estrogen receptor content was also investigated on adjacent tissue sections. Ki-67 values ranged from 1 to 75%, with a median value of 10%. Premenopausal patients had greater Ki-67 values (median value, 14.1%) than postmenopausal ones (median value, 9.8%). The authors observed no correlation with lymph nodal involvement, whereas a statistically significant relationship with tumor size was found (P < 0.01). An inverse correlation (Spearman's coefficient = -0.56; P < 0.001) was seen between Ki-67 values and nuclear estrogen receptor content. These results, similar to those reported for other kinetic measurements, suggest that in situ detection of Ki-67 proliferation rate is a useful method for obtaining cell cycle information. Follow-up studies will be needed to assess an eventual prognostic relevance.
引用
收藏
页码:30 / 34
页数:5
相关论文
共 39 条
[1]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[2]   THE USE OF THE MONOCLONAL-ANTIBODY KI-67 IN THE IDENTIFICATION OF PROLIFERATING CELLS - APPLICATION TO SURGICAL NEUROPATHOLOGY [J].
BURGER, PC ;
SHIBATA, T ;
KLEIHUES, P .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1986, 10 (09) :611-617
[3]  
CAMPLEJOHN RS, 1989, CELL TISSUE KINET, V22, P124
[4]  
DESOMBRE ER, 1986, CANCER RES, V46, P4256
[5]  
FLEISS JL, 1973, STATISTICAL METHODS, P143
[6]  
GENTILI C, 1981, CANCER, V48, P974, DOI 10.1002/1097-0142(19810815)48:4<974::AID-CNCR2820480420>3.0.CO
[7]  
2-#
[8]  
GERDES J, 1987, AM J PATHOL, V129, P486
[9]  
Gerdes J, 1984, Hematol Oncol, V2, P365
[10]  
GERDES J, 1984, J IMMUNOL, V133, P1710